Drug
Navtemadlin clinical trials
Also written KRT-232 and AMG 232.
Keep track of what changes. Save the navtemadlin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 2 |
| 2021 | 6 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 5
Kartos Therapeutics, Inc. (12) · National Cancer Institute (NCI) (5) · Telios Pharma, Inc. (2)
Often tested with
Tested in the same studies.
Flixebrutinib (2) · Cytarabine (1) · Idarubicin (1) · Decitabine (1) · Venetoclax (1) · Dabrafenib (1) · Carfilzomib (1) · Dexamethasone (1)
Studies
Open first, then newest update. How each study uses navtemadlin is read from its arms, and is right about nine times in ten.
Testing it · 19
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibRecruitingPhase 3Kartos Therapeutics, Inc.NCT06479135Written as Navtemadlin
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerRecruitingPhase 2/3Kartos Therapeutics, Inc.NCT05797831Written as Navtemadlin
- KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentRecruitingPhase 2/3Kartos Therapeutics, Inc.NCT03662126Written as KRT-232
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingPhase 2Kartos Therapeutics, Inc.NCT04878003Written as KRT-232
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04190550Written as Navtemadlin
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03041688Written as Navtemadlin
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedPhase 1National Cancer Institute (NCI)NCT03031730Written as Navtemadlin
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedPhase 1National Cancer Institute (NCI)NCT03107780Written as Navtemadlin
- Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue SarcomaCompletedPhase 1National Cancer Institute (NCI)NCT03217266Written as Navtemadlin
- Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung CancerWithdrawnPhase 1/2Kartos Therapeutics, Inc.NCT05705466Written as Navtemadlin
- KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung CancerTerminatedPhase 2Kartos Therapeutics, Inc.NCT05027867Written as KRT-232
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsActive, not recruitingPhase 1/2Telios Pharma, Inc.NCT02825836Written as Navtemadlin
- TL-895 and KRT-232 Study in Acute Myeloid LeukemiaActive, not recruitingPhase 1/2Telios Pharma, Inc.NCT04669067Written as KRT-232
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownPhase 1/2Kartos Therapeutics, Inc.NCT04502394Written as KRT-232
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownPhase 1/2Kartos Therapeutics, Inc.NCT04485260Written as KRT-232
- A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaCompletedPhase 1Kartos Therapeutics, Inc.NCT01723020Written as AMG 232
- A Phase 1b/2a Study Evaluating AMG 232 in Metastatic MelanomaCompletedPhase 1Kartos Therapeutics, Inc.NCT02110355Written as AMG 232
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraStatus unknownPhase 2Kartos Therapeutics, Inc.NCT03669965Written as KRT-232
- A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaCompletedPhase 1Kartos Therapeutics, Inc.NCT02016729Written as AMG 232
Given in every arm · 4 — navtemadlin is usual care beside what is tested
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT03787602Written as KRT-232
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT04640532Written as KRT-232
- KRT-232 and TKI Study in Chronic Myeloid LeukemiaRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT04835584Written as KRT-232
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedPhase 1/2Kartos Therapeutics, Inc.NCT04113616Written as KRT-232
Codes
What other systems call navtemadlin · ClinicalTrials.gg INT015519
- UNII (FDA) 7R7G6EH5ULNAVTEMADLINOne source FDA
- NCI Thesaurus C116624NavtemadlinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7R7G6EH5UL | NAVTEMADLIN | One source FDA |
| NCI Thesaurus | C116624 | Navtemadlin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.